Prospective evaluation of neuromediators during treatment with docetaxel in castration resistant prostate cancer.

Hardenberg, Jost von; Schwartz, Maike; Bolenz, Christian; Weiß, Christel; Werner, Thorsten; Fuxius, Stefan; Mueller, Markus; Frangenheim, Thomas; Heinrich, Elmar

doi:10.1200/jco.2016.34.15_suppl.e16609

Cited by 2 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of the methodologic quality assessment of the studies [24][25][26][27][28][29] are presented shown in Table 2. These experiments were launched by different multi-center regions, so that the external validity is good overall.…”

Section: Study Qualitymentioning

confidence: 99%

“…As with the characteristics reflected by Table 1, all included studies were hospital-based retrospective validation studies, of which 3 were cohort studies [24][25][26] and 3 were case-control studies [27][28][29]. All publications were published from 2010 through 2017.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…All publications were published from 2010 through 2017. A total of 234 participants were included in the analysis, 168 of whom received novel hormonal therapy (chemotherapy pretreated or chemotherapy-naïve) such as AA [24,25,28] or ENZ [27] (range of sample sizes = 35-48); the remaining patients only received chemotherapy as drugs docetaxel [26,29]. The mean age of participants was 71.3 years across all studies.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Three hundred and fifty-three papers were identified through joint search keywords and their free-text words from 3 electronic databases and from these papers, 146 articles were excluded by removing of duplicates and 194 were precluded based on titles and abstracts. Finally, 6 of remaining 13 trials met the inclusion criteria and were selected for this meta-analysis [24][25][26][27][28][29].…”

Section: Study Identificationmentioning

confidence: 99%

“…In univariate analysis, 6 studies [24][25][26][27][28][29] were involved in current meta-analysis to assess the prognostic value of serum neuroendocrine markers in post-treat- For cohort studies: (1) Indicates that the exposed cohort was representative of the population; (2) Indicates that the non-exposed cohort was drawn from the same population; (3) Indicates that the exposure ascertainment was from secure records or a structured interview; (4) Indicates that outcome of interest was not present at start of study; (5) Indicates that the cohorts were comparable for age and gender; (6) Indicates that the cohorts were comparable on all additional factor(s) reported; (7) Indicates that outcome was assessed from a secure record; (8) Indicates that follow-up was long enough for outcomes to occur; (9) Indicates that follow-up was complete.…”

Section: Meta-analysis Of Osmentioning

confidence: 99%

See 4 more Smart Citations

Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

Purpose: To evaluate whether serum neuroendocrine markers could effectively predict treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Methods: The PubMed, Cochrane Library and Embase databases were sought to identify eligible studies concerning serum neuroendocrine markers and the prognosis of post-treatment mCRPC from inception to April 2018. The association between serum neuroendocrine markers, that is, chromogranin A (CgA) and neurone-specific enolase (NSE), levels and the prognosis of post-treatment mCRPC were summarized using a random-effects model and hazard ratio (HR) with 95% CI Sensitivity analyses were conducted to assess potential bias. Results: A total of 234 participants are included in this meta-analysis (mean age = 71.3 years) from 6 studies. The pooled results show that higher markers’ levels at baseline in patients were associated with unfavorable overall survival (OS; univariate analysis: HR 3.775, 95% CI 1.469–9.698, p = 0.006; multivariate analysis: HR 3.838, 95% CI 1.774–8.304, p = 0.001), and a similar situation was observed in progression-free survival (PFS; univariate analysis: HR 2.785, 95% CI 1.315–5.898, p = 0.007; multivariate analysis: HR 1.266, 95% CI 1.017–1.577, p = 0.035). Estimates of the total effects were generally consistent in the sensitivity analysis. Publication bias was observed when performing the univariate analysis of PFS, and we have the explanation accordingly. Conclusions: The results of this pooled analysis confirm serum neuroendocrine markers could be the effective predictor of treatment outcome in patients with mCRPC. In addition, a combination of CgA and NSE is more valuable to predict worse OS. Further randomized case-control trials are required to validate this relationship.

show abstract

Section: Study Qualitymentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Identificationmentioning

confidence: 99%

Section: Meta-analysis Of Osmentioning

confidence: 99%

See 3 more Smart Citations

Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer

et al. 2022

View full text Add to dashboard Cite

Background: The neuroendocrine (NE) pathway cannot be ignored as a mechanism for castration-resistant prostate cancer (CRPC) progression. The neuromediator, gastrin-releasing peptide (GRP) may be involved in the aberrant activation of the normal androgen receptor (AR) and increased AR variants. This study focused on plasma levels of progastrin-releasing peptide (ProGRP) and examined the treatment outcomes with androgen receptor axis-targeted (ARAT) agents.Methods: One hundred patients with metastatic CRPC were enrolled. Enzalutamide (ENZ) or abiraterone acetate/prednisone (AA/P) were administered to 50 patients each in a nonrandomized manner as a first-line or later choice. Plasma ProGRP levels were determined using a chemiluminescent enzyme immunoassay, and data were collected prospectively. The study endpoints were prostate-specific antigen (PSA) response and survival estimates.Results: In the ENZ series, ProGRP levels correlated with the maximum PSA change from baseline (high ProGRP: À34.5% vs. low ProGRP: À85.7% p = .033). PSA progression-free survival (PFS), radiographic/symptomatic (r/s) PFS, and overall survival (OS) in patients with high ProGRP were significantly worse than those in patients with low ProGRP (median PSA-PFS: 3.3 vs. 10.0 months, p = .001, r/s PFS: 5.0 vs. 15.0 months, p < 0.001, and OS 17.5 vs. 49.0 months, p < .001, respectively).In addition, ProGRP showed an independent predictive value for all survival estimates in multivariate analyses. In the AA/P series, ProGRP levels did not correlate with the PSA change or predict PSA-PFS and r/s PFS, but they maintained a significant difference in OS (19.0 vs. 48.0 months, p = .003).Conclusions: Plasma ProGRP provides a consistent predictive value for OS in metastatic CRPC patients who underwent therapy with ARAT agents. Meanwhile, ProGRP showed different predictive profiles for PSA-and r/s PFS between ENZ and

show abstract

Prospective evaluation of neuromediators during treatment with docetaxel in castration resistant prostate cancer.

Cited by 2 publications

References 0 publications

Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis

Plasma progastrin‐releasing peptide level shows different predictive profiles for treatment response by androgen receptor axis‐targeted agents in patients with metastatic castration‐resistant prostate cancer

Contact Info

Product

Resources

About